8-azaguanine

DB01667

small molecule experimental

Deskripsi

8-azaguanine is one of the early purine analogs showing antineoplastic activity. It functions as an antimetabolite and is easily incorporated into ribonucleic acids.

Struktur Molekul 2D

Berat 152.1142
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

638 Data
Deferasirox The serum concentration of 8-azaguanine can be increased when it is combined with Deferasirox.
Peginterferon alfa-2b The serum concentration of 8-azaguanine can be increased when it is combined with Peginterferon alfa-2b.
Leflunomide The serum concentration of 8-azaguanine can be decreased when it is combined with Leflunomide.
Teriflunomide The serum concentration of 8-azaguanine can be decreased when it is combined with Teriflunomide.
Regadenoson 8-azaguanine may decrease effectiveness of Regadenoson as a diagnostic agent.
Adalimumab The serum concentration of 8-azaguanine can be decreased when it is combined with Adalimumab.
Adenosine The therapeutic efficacy of Adenosine can be decreased when used in combination with 8-azaguanine.
Allopurinol The serum concentration of 8-azaguanine can be increased when it is combined with Allopurinol.
Carbamazepine The serum concentration of 8-azaguanine can be decreased when it is combined with Carbamazepine.
Cimetidine The metabolism of 8-azaguanine can be decreased when combined with Cimetidine.
Disulfiram The serum concentration of 8-azaguanine can be increased when it is combined with Disulfiram.
Febuxostat The serum concentration of the active metabolites of 8-azaguanine can be increased when 8-azaguanine is used in combination with Febuxostat.
Fluvoxamine The metabolism of 8-azaguanine can be decreased when combined with Fluvoxamine.
Formoterol The risk or severity of hypokalemia can be increased when 8-azaguanine is combined with Formoterol.
Indacaterol The risk or severity of adverse effects can be increased when 8-azaguanine is combined with Indacaterol.
Isoniazid The serum concentration of 8-azaguanine can be increased when it is combined with Isoniazid.
Lithium citrate The serum concentration of Lithium citrate can be decreased when it is combined with 8-azaguanine.
Lithium carbonate The serum concentration of Lithium carbonate can be decreased when it is combined with 8-azaguanine.
Lithium hydroxide The serum concentration of Lithium hydroxide can be decreased when it is combined with 8-azaguanine.
Mexiletine The metabolism of 8-azaguanine can be decreased when combined with Mexiletine.
Olodaterol 8-azaguanine may increase the hyperkalemic activities of Olodaterol.
Pancuronium The therapeutic efficacy of Pancuronium can be decreased when used in combination with 8-azaguanine.
Pentoxifylline The serum concentration of 8-azaguanine can be increased when it is combined with Pentoxifylline.
Phenytoin The serum concentration of 8-azaguanine can be decreased when it is combined with Phenytoin.
Fosphenytoin The serum concentration of 8-azaguanine can be decreased when it is combined with Fosphenytoin.
Propafenone The serum concentration of 8-azaguanine can be increased when it is combined with Propafenone.
Quinine The serum concentration of 8-azaguanine can be increased when it is combined with Quinine.
Quinidine The serum concentration of 8-azaguanine can be increased when it is combined with Quinidine.
Riociguat 8-azaguanine may increase the hypotensive activities of Riociguat.
Thiabendazole The metabolism of 8-azaguanine can be decreased when combined with Thiabendazole.
Ticlopidine The metabolism of 8-azaguanine can be decreased when combined with Ticlopidine.
Zafirlukast The serum concentration of Zafirlukast can be decreased when it is combined with 8-azaguanine.
Probenecid The serum concentration of 8-azaguanine can be increased when it is combined with Probenecid.
Abiraterone The serum concentration of 8-azaguanine can be increased when it is combined with Abiraterone.
Isoprenaline The serum concentration of 8-azaguanine can be decreased when it is combined with Isoprenaline.
Cyproterone acetate The metabolism of 8-azaguanine can be increased when combined with Cyproterone acetate.
Amphetamine The risk or severity of adverse effects can be increased when Amphetamine is combined with 8-azaguanine.
Phentermine The risk or severity of adverse effects can be increased when Phentermine is combined with 8-azaguanine.
Midodrine The risk or severity of adverse effects can be increased when Midodrine is combined with 8-azaguanine.
Norepinephrine The risk or severity of adverse effects can be increased when Norepinephrine is combined with 8-azaguanine.
Phenylephrine The risk or severity of adverse effects can be increased when Phenylephrine is combined with 8-azaguanine.
Phenylpropanolamine The risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with 8-azaguanine.
Labetalol The risk or severity of adverse effects can be increased when Labetalol is combined with 8-azaguanine.
Metaraminol The risk or severity of adverse effects can be increased when Metaraminol is combined with 8-azaguanine.
Epinephrine The risk or severity of adverse effects can be increased when Epinephrine is combined with 8-azaguanine.
Methoxamine The risk or severity of adverse effects can be increased when Methoxamine is combined with 8-azaguanine.
Orciprenaline The risk or severity of adverse effects can be increased when Orciprenaline is combined with 8-azaguanine.
Phenmetrazine The risk or severity of adverse effects can be increased when Phenmetrazine is combined with 8-azaguanine.
Dobutamine The risk or severity of adverse effects can be increased when Dobutamine is combined with 8-azaguanine.
Pseudoephedrine The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with 8-azaguanine.
Benzphetamine The risk or severity of adverse effects can be increased when Benzphetamine is combined with 8-azaguanine.
Ritodrine The risk or severity of adverse effects can be increased when Ritodrine is combined with 8-azaguanine.
Terbutaline The risk or severity of adverse effects can be increased when Terbutaline is combined with 8-azaguanine.
Oxymetazoline The risk or severity of adverse effects can be increased when Oxymetazoline is combined with 8-azaguanine.
Diethylpropion The risk or severity of adverse effects can be increased when Diethylpropion is combined with 8-azaguanine.
Dopamine The risk or severity of adverse effects can be increased when Dopamine is combined with 8-azaguanine.
Acebutolol The risk or severity of adverse effects can be increased when Acebutolol is combined with 8-azaguanine.
Lisdexamfetamine The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with 8-azaguanine.
Fenoterol The risk or severity of adverse effects can be increased when Fenoterol is combined with 8-azaguanine.
Ephedrine The risk or severity of adverse effects can be increased when Ephedrine is combined with 8-azaguanine.
Mephentermine The risk or severity of adverse effects can be increased when Mephentermine is combined with 8-azaguanine.
Procaterol The risk or severity of adverse effects can be increased when Procaterol is combined with 8-azaguanine.
Clenbuterol The risk or severity of adverse effects can be increased when Clenbuterol is combined with 8-azaguanine.
MMDA The risk or severity of adverse effects can be increased when MMDA is combined with 8-azaguanine.
Midomafetamine The risk or severity of adverse effects can be increased when Midomafetamine is combined with 8-azaguanine.
2,5-Dimethoxy-4-ethylamphetamine The risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with 8-azaguanine.
4-Bromo-2,5-dimethoxyamphetamine The risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with 8-azaguanine.
Tenamfetamine The risk or severity of adverse effects can be increased when Tenamfetamine is combined with 8-azaguanine.
Chlorphentermine The risk or severity of adverse effects can be increased when Chlorphentermine is combined with 8-azaguanine.
Methylenedioxyethamphetamine The risk or severity of adverse effects can be increased when Methylenedioxyethamphetamine is combined with 8-azaguanine.
Dextroamphetamine The risk or severity of adverse effects can be increased when Dextroamphetamine is combined with 8-azaguanine.
Metamfetamine The risk or severity of adverse effects can be increased when Metamfetamine is combined with 8-azaguanine.
Celiprolol The risk or severity of adverse effects can be increased when Celiprolol is combined with 8-azaguanine.
Nylidrin The risk or severity of adverse effects can be increased when Nylidrin is combined with 8-azaguanine.
Tetryzoline The risk or severity of adverse effects can be increased when Tetryzoline is combined with 8-azaguanine.
Tyramine The risk or severity of adverse effects can be increased when Tyramine is combined with 8-azaguanine.
Isoxsuprine The risk or severity of adverse effects can be increased when Isoxsuprine is combined with 8-azaguanine.
Etilefrine The risk or severity of adverse effects can be increased when Etilefrine is combined with 8-azaguanine.
Synephrine The risk or severity of adverse effects can be increased when Synephrine is combined with 8-azaguanine.
Hydroxyamphetamine The risk or severity of adverse effects can be increased when Hydroxyamphetamine is combined with 8-azaguanine.
Iofetamine I-123 The risk or severity of adverse effects can be increased when Iofetamine I-123 is combined with 8-azaguanine.
Racepinephrine The risk or severity of adverse effects can be increased when Racepinephrine is combined with 8-azaguanine.
Ritobegron The risk or severity of adverse effects can be increased when Ritobegron is combined with 8-azaguanine.
Bucindolol The risk or severity of adverse effects can be increased when Bucindolol is combined with 8-azaguanine.
Tramazoline The risk or severity of adverse effects can be increased when Tramazoline is combined with 8-azaguanine.
Mephedrone The risk or severity of adverse effects can be increased when Mephedrone is combined with 8-azaguanine.
Fenozolone The risk or severity of adverse effects can be increased when Fenozolone is combined with 8-azaguanine.
Methoxyphenamine The risk or severity of adverse effects can be increased when Methoxyphenamine is combined with 8-azaguanine.
Tretoquinol The risk or severity of adverse effects can be increased when Tretoquinol is combined with 8-azaguanine.
Gepefrine The risk or severity of adverse effects can be increased when Gepefrine is combined with 8-azaguanine.
Epanolol The risk or severity of adverse effects can be increased when Epanolol is combined with 8-azaguanine.
Prenalterol The risk or severity of adverse effects can be increased when Prenalterol is combined with 8-azaguanine.
Mefenorex The risk or severity of adverse effects can be increased when Mefenorex is combined with 8-azaguanine.
2,5-Dimethoxy-4-ethylthioamphetamine The risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with 8-azaguanine.
Esmolol The risk or severity of adverse effects can be increased when Esmolol is combined with 8-azaguanine.
Betaxolol The risk or severity of adverse effects can be increased when Betaxolol is combined with 8-azaguanine.
Metoprolol The risk or severity of adverse effects can be increased when Metoprolol is combined with 8-azaguanine.
Atenolol The risk or severity of adverse effects can be increased when Atenolol is combined with 8-azaguanine.
Timolol The risk or severity of adverse effects can be increased when Timolol is combined with 8-azaguanine.
Sotalol The risk or severity of adverse effects can be increased when Sotalol is combined with 8-azaguanine.

Target Protein

Purine nucleoside phosphorylase PNP

Referensi & Sumber

Artikel (PubMed)
  • PMID: 22043012
    Michels AW, Ostrov DA, Zhang L, Nakayama M, Fuse M, McDaniel K, Roep BO, Gottlieb PA, Atkinson MA, Eisenbarth GS: Structure-based selection of small molecules to alter allele-specific MHC class II antigen presentation. J Immunol. 2011 Dec 1;187(11):5921-30. doi: 10.4049/jimmunol.1100746. Epub 2011 Oct 31.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul